JanOne Inc. announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). Although meth use has been decreasing in younger individuals, in people over 26 years old, it has been growing at a CAGR of 13% p.a., with just over 150,000 new users of the drug annually. The death rate of drug overdoses have increased by over 300% in the last 10 years.

Although the projected market for treatments of methamphetamine abuse is close to $500M, there are no FDA-approved medications for the treatment of methamphetamine use disorder.